FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226050577> ?p ?o ?g. }

• W4226050577 abstract "Oral cavity and oropharyngeal cancers are the most common cancers arising in the head and neck. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely to be advanced at the time of diagnosis, are managed with radiotherapy or chemoradiation. Surgery for oral cancers can be disfiguring and both surgery and radiotherapy have significant functional side effects. The development of new chemotherapy agents, new combinations of agents and changes in the relative timing of surgery, radiotherapy, and chemotherapy treatments may potentially bring about increases in both survival and quality of life for this group of patients. This review updates one last published in 2011.To determine whether chemotherapy, in addition to radiotherapy and/or surgery for oral cavity and oropharyngeal squamous cell carcinoma results in improved overall survival, improved disease-free survival and/or improved locoregional control, when incorporated as either induction therapy given prior to locoregional treatment (i.e. radiotherapy or surgery), concurrent with radiotherapy or in the adjuvant (i.e. after locoregional treatment with radiotherapy or surgery) setting.An information specialist searched 4 bibliographic databases up to 15 September 2021 and used additional search methods to identify published, unpublished and ongoing studies.We included randomised controlled trials (RCTs) where more than 50% of participants had primary tumours in the oral cavity or oropharynx, and that evaluated the addition of chemotherapy to other treatments such as radiotherapy and/or surgery, or compared two or more chemotherapy regimens or modes of administration.For this update, we assessed the new included trials for their risk of bias and at least two authors extracted data from them. Our primary outcome was overall survival (time to death from any cause). Secondary outcomes were disease-free survival (time to disease recurrence or death from any cause) and locoregional control (response to primary treatment). We contacted trial authors for additional information or clarification when necessary.We included 100 studies with 18,813 participants. None of the included trials were at low risk of bias. For induction chemotherapy, we reported the results for contemporary regimens that will be of interest to clinicians and people being treated for oral cavity and oropharyngeal cancers. Overall, there is insufficient evidence to clearly demonstrate a survival benefit from induction chemotherapy with platinum plus 5-fluorouracil prior to radiotherapy (hazard ratio (HR) for death 0.85, 95% confidence interval (CI) 0.70 to 1.04, P = 0.11; 7427 participants, 5 studies; moderate-certainty evidence), prior to surgery (HR for death 1.06, 95% CI 0.71 to 1.60, P = 0.77; 198 participants, 1 study; low-certainty evidence) or prior to concurrent chemoradiation (CRT) with cisplatin (HR for death 0.71, 95% CI 0.37 to 1.35, P = 0.30; 389 participants, 2 studies; low-certainty evidence). There is insufficient evidence to support the use of an induction chemotherapy regimen with cisplatin plus 5-fluorouracil plus docetaxel prior to CRT with cisplatin (HR for death 1.08, 95% CI 0.80 to 1.44, P = 0.63; 760 participants, 3 studies; low-certainty evidence). There is insufficient evidence to support the use of adjuvant chemotherapy over observation only following surgery (HR for death 0.95, 95% CI 0.73 to 1.22, P = 0.67; 353 participants, 5 studies; moderate-certainty evidence). Among studies that compared post-surgical adjuvant CRT, as compared to post-surgical RT, adjuvant CRT showed a survival benefit (HR 0.84, 95% CI 0.72 to 0.98, P = 0.03; 1097 participants, 4 studies; moderate-certainty evidence). Primary treatment with CRT, as compared to radiotherapy alone, was associated with a reduction in the risk of death (HR for death 0.74, 95% CI 0.67 to 0.83, P < 0.00001; 2852 participants, 24 studies; moderate-certainty evidence). AUTHORS' CONCLUSIONS: The results of this review demonstrate that chemotherapy in the curative-intent treatment of oral cavity and oropharyngeal cancers only seems to be of benefit when used in specific circumstances together with locoregional treatment. The evidence does not show a clear survival benefit from the use of induction chemotherapy prior to radiotherapy, surgery or CRT. Adjuvant CRT reduces the risk of death by 16%, as compared to radiotherapy alone. Concurrent chemoradiation as compared to radiation alone is associated with a greater than 20% improvement in overall survival; however, additional research is required to inform how the specific chemotherapy regimen may influence this benefit." @default.
• W4226050577 created "2022-05-05" @default.
• W4226050577 creator A5008282524 @default.
• W4226050577 creator A5008847761 @default.
• W4226050577 creator A5048523520 @default.
• W4226050577 creator A5050551405 @default.
• W4226050577 creator A5079955328 @default.
• W4226050577 creator A5081974212 @default.
• W4226050577 creator A5084212458 @default.
• W4226050577 creator A5089081788 @default.
• W4226050577 date "2021-12-20" @default.
• W4226050577 modified "2023-10-17" @default.
• W4226050577 title "Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy" @default.
• W4226050577 cites W1138664098 @default.
• W4226050577 cites W1219369450 @default.
• W4226050577 cites W1445004593 @default.
• W4226050577 cites W1482866244 @default.
• W4226050577 cites W1503488050 @default.
• W4226050577 cites W151012557 @default.
• W4226050577 cites W151172257 @default.
• W4226050577 cites W1527302031 @default.
• W4226050577 cites W1529679568 @default.
• W4226050577 cites W1546296458 @default.
• W4226050577 cites W1554133756 @default.
• W4226050577 cites W157240402 @default.
• W4226050577 cites W1598602811 @default.
• W4226050577 cites W1607129285 @default.
• W4226050577 cites W1681088090 @default.
• W4226050577 cites W1746656852 @default.
• W4226050577 cites W1759456481 @default.
• W4226050577 cites W1784479792 @default.
• W4226050577 cites W180480091 @default.
• W4226050577 cites W1832283178 @default.
• W4226050577 cites W1844352038 @default.
• W4226050577 cites W1845783823 @default.
• W4226050577 cites W1863321637 @default.
• W4226050577 cites W1898337686 @default.
• W4226050577 cites W1904941427 @default.
• W4226050577 cites W1909654468 @default.
• W4226050577 cites W1913074237 @default.
• W4226050577 cites W1926198890 @default.
• W4226050577 cites W1928010366 @default.
• W4226050577 cites W1953283500 @default.
• W4226050577 cites W1956256739 @default.
• W4226050577 cites W1964327353 @default.
• W4226050577 cites W1966675362 @default.
• W4226050577 cites W1966854325 @default.
• W4226050577 cites W1968045554 @default.
• W4226050577 cites W1968362080 @default.
• W4226050577 cites W1968737726 @default.
• W4226050577 cites W1968741994 @default.
• W4226050577 cites W1971288558 @default.
• W4226050577 cites W1971986240 @default.
• W4226050577 cites W1972704549 @default.
• W4226050577 cites W1973165463 @default.
• W4226050577 cites W1973485852 @default.
• W4226050577 cites W1975122248 @default.
• W4226050577 cites W1975828423 @default.
• W4226050577 cites W1976327410 @default.
• W4226050577 cites W1976347442 @default.
• W4226050577 cites W1976896380 @default.
• W4226050577 cites W1977306578 @default.
• W4226050577 cites W1978544089 @default.
• W4226050577 cites W1979052319 @default.
• W4226050577 cites W1979513037 @default.
• W4226050577 cites W1981089143 @default.
• W4226050577 cites W1981465849 @default.
• W4226050577 cites W1982153752 @default.
• W4226050577 cites W1983019810 @default.
• W4226050577 cites W1983970003 @default.
• W4226050577 cites W1984190035 @default.
• W4226050577 cites W1985434636 @default.
• W4226050577 cites W1986884101 @default.
• W4226050577 cites W1988556097 @default.
• W4226050577 cites W1989087937 @default.
• W4226050577 cites W1989312431 @default.
• W4226050577 cites W1991177017 @default.
• W4226050577 cites W1991585972 @default.
• W4226050577 cites W1992815288 @default.
• W4226050577 cites W1992977889 @default.
• W4226050577 cites W1994314532 @default.
• W4226050577 cites W1994889035 @default.
• W4226050577 cites W1996101068 @default.
• W4226050577 cites W199648135 @default.
• W4226050577 cites W1996907118 @default.
• W4226050577 cites W1996979452 @default.
• W4226050577 cites W1997339854 @default.
• W4226050577 cites W1998118760 @default.
• W4226050577 cites W1998289040 @default.
• W4226050577 cites W1998694433 @default.
• W4226050577 cites W2000419042 @default.
• W4226050577 cites W2001195228 @default.
• W4226050577 cites W2001368991 @default.
• W4226050577 cites W2004805729 @default.
• W4226050577 cites W2005084041 @default.
• W4226050577 cites W2006350301 @default.
• W4226050577 cites W2007531271 @default.
• W4226050577 cites W2007873654 @default.
• W4226050577 cites W2008361242 @default.
• W4226050577 cites W2010402293 @default.

• next